Welcome Gathering by TBA
A transfer service will be arranged for forum participants from the Swissôtel Wellness Resort Alatau Almaty hotel to the venue and back.

Moderator: Vyacheslav Lokshin, President, Association of International Pharmaceutical Manufacturers

• Impact of geopolitical changes on the manufacturing and supply of medicines
• Investments in the pharmaceutical sectors of the EAEU countries, strategies of global and local players
• Role of Big Pharma and government collaboration in improving access to new drugs
• Impact of digital development on the healthcare system

Moderator: answers from regulators, questions from pharmaceutical companies

Relevance: With the introduction of a unified system for registration of medicines in the EAEU countries, companies face new requirements and procedures that may affect the timing of drug entry into the market and overall availability. Discussion of this topic will be relevant in light of the integration of countries and the desire to simplify access to medicines for the population.

• How can unified registration speed up the process of bringing new drugs to markets?
• Advantages and disadvantages of a unified system for manufacturers and distributors.
• Expectations and reality: how do companies adapt to new requirements?
• What steps can be taken to optimize the registration process?
• What are the main challenges companies face in the unified registration process?

Moderator: Marina Durmanova, President, Association for the Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan

• Approaches to price regulation of drug provision within the framework of public procurement programs in the countries of the Eurasian region and CIS countries. Impact on the availability of medicines
• Provision of medicines for the treatment of orphan diseases within the framework of the Eurasian Union and the experience of other countries
• Reference pricing mechanisms
• How price regulation works – the experience of other countries and regions
• Deregulation of retail prices for medicines in the commercial segment in the Republic of Kazakhstan

Moderator: Vadim Kukava, Executive Director, "Inpharma" Association

Relevance:
How to support the development of new, life-saving medicines while ensuring their availability to patients? Patents play a critical role in protecting the intellectual property of pharmaceutical companies by creating incentives for expensive and time-consuming research and development (R&D). But once a patent expires, the question of availability arises — how to ensure that needed drugs do not remain expensive and unavailable to most patients? Indeed, against the backdrop of challenges associated with the need for affordable innovative solutions, pressure on pharmaceutical companies from governments, regulators and society is increasing.

• How to ensure a balance incentives for innovation, access to medicines for patients and contribution to economic development?
• Current challenges and trends in the protection of intellectual property rights for pharmaceutical developments.
• What initiatives are aimed at harmonizing standards and strengthening the protection of intellectual property rights at the level of the EAEU countries?

Moderator: Marina DURMANOVA – president of the Association for the Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan

• Impact of labeling systems on transparency and safety of medicines
• Impact on the work of wholesale companies and pharmacy organizations
• How can labeling help in the fight against counterfeit drugs? Are there other regulatory tools?
• Transition to new standards: challenges and solutions for the entire supply chain
• What are the main benefits of labelling systems for end consumers?
• Labeling of unregistered medicines in the Republic of Kazakhstan

• Key figures and trends: Presentation of the latest data from analytical agencies on the dynamics of market growth and sales volume in the pharmaceutical industry in the EAEU countries. Discussion of key indicators for recent years and forecasts for 2024-2025.
• How is the demand for different categories of drugs changing (innovative drugs, generics, over-the-counter drugs, biosimilars)? Which segments are showing the most active growth?
• How do the markets of Russia, Kazakhstan, Uzbekistan, Belarus, Armenia and Kyrgyzstan differ in terms of volumes and growth rates? Influence of economic and regulatory factors on the development of pharmaceutical markets in each country.
• Impact of consumer behavior on the drug market: How are patient needs and preferences changing in the EAEU? For example, is there a growing demand for natural products, online consultations and purchasing drugs through electronic platforms?

Speakers: Representatives of analytical agencies and consulting companies, Regulators and representatives of government agencies of the EAEU countries, Heads and managers of pharmaceutical companies.

1-on-1 meetings with distributors will be held throughout the session in a separate room. Each distributor will be represented by several representatives. A time slot will be allocated for each distributor. The duration of the meeting is 15 minutes. During this time, you will have the opportunity to introduce your company, products or services, find out the need for them from the distributor, ask questions and establish contact for the future. These 1-on-1 meetings offer a unique opportunity to personally meet and talk with representatives of local distributors.